The estimated Net Worth of Michael G. Bator is at least $276 millier dollars as of 13 December 2023. Mr. Bator owns over 37,594 units of Cytosorbents Corp stock worth over $125,394 and over the last 9 years he sold CTSO stock worth over $0. In addition, he makes $150,950 as Independent Director at Cytosorbents Corp.
Sign up
Mr. Bator CTSO stock SEC Form 4 insiders trading
Michael has made over 5 trades of the Cytosorbents Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 37,594 units of CTSO stock worth $50,000 on 13 December 2023.
The largest trade he's ever made was buying 37,594 units of Cytosorbents Corp stock on 13 December 2023 worth over $50,000. On average, Michael trades about 3,740 units every 183 days since 2015. As of 13 December 2023 he still owns at least 125,394 units of Cytosorbents Corp stock.
You can see the complete history of Mr. Bator stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Bator biography
Michael G. Bator serves as Independent Director of the Company. Mr. Bator has been a director of CytoSorbents since July 2015. Mr. Bator is a founder and partner of Quartz Advisory Group, LLC, a capital markets investment bank. Mr. Bator is the founder and partner of Certus Advisory, a consulting firm he founded in February 2015. From April 2015 to December 2016, Mr. Bator was the Chief Financial Officer of Trek Therapeutics, a development stage pharmaceutical company. From January 2001 until February 2015, Mr. Bator held several positions with Jennison Associates, a United States mutual and pension fund management company, where he was most recently Managing Director, Healthcare Research. Prior to that time, he worked in management consulting with Cambridge Pharma Consultancy, Lexington Strategy, and The Boston Consulting Group. Since March 2015, Mr. Bator has served on the board of directors of 3DBio Corporation, a private company focused on bioprinted cartilage implants used in reconstructive and orthopedic surgery. Since June 2017, Mr. Bator has served on the board of directors of Hippo Technologies, LLC., a technology company focused on helping consumers manage their prescriptions. Mr. Bator received his MBA in Finance from Wharton Business School at the University of Pennsylvania, and his BA from Princeton University.
What is the salary of Michael Bator?
As the Independent Director of Cytosorbents Corp, the total compensation of Michael Bator at Cytosorbents Corp is $150,950. There are 10 executives at Cytosorbents Corp getting paid more, with Phillip Chan having the highest compensation of $1,404,380.
How old is Michael Bator?
Michael Bator is 56, he's been the Independent Director of Cytosorbents Corp since 2015. There are 8 older and 3 younger executives at Cytosorbents Corp. The oldest executive at Cytosorbents Corp is Dr. Robert H. Bartlett, 82, who is the Co-Chairman of Cardiac Surgery Advisory Board & Consultant.
What's Michael Bator's mailing address?
Michael's mailing address filed with the SEC is C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON, NJ, 08540.
Insiders trading at Cytosorbents Corp
Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus et Phillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.
What does Cytosorbents Corp do?
cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
What does Cytosorbents Corp's logo look like?
Complete history of Mr. Bator stock trades at Cytosorbents Corp
Cytosorbents Corp executives and stock owners
Cytosorbents Corp executives and other stock owners filed with the SEC include:
-
Phillip Chan,
President, Chief Executive Officer, Director -
Vincent Capponi,
Chief Operating Officer -
Kathleen Bloch,
Chief Financial Officer -
Dr. Phillip P. Chan,
CEO & Director -
Vincent J. Capponi M.S., MS,
Pres & COO -
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.,
Chief Medical Officer -
Kathleen P. Bloch CPA, M.B.A., MBA, CPA,
CFO & Sec. -
Al Kraus,
Independent Non-Executive Chairman of the Board -
Alan Sobel,
Independent Director -
Edward Jones,
Independent Director -
Michael Bator,
Independent Director -
Dr. Robert H. Bartlett,
Co-Chairman of Cardiac Surgery Advisory Board & Consultant -
Christopher Cramer,
VP of Bus. Devel. -
Dr. Christian Steiner M.D.,
Exec. VP of Sales & Marketing -
Terri Anne Powers M.B.A.,
VP of Investor Relations & Corp. Communications -
Peter J Mariani,
Chief Financial Officer -
Eric R. Mortensen,
Chief Medical Officer -
Robert Hawes Bartlett,
Chief Medical Officer -
Investment Fund, Lp Njtc,
10% owner -
Joseph Rubin,
Director -
Ronald Berger,
Interim CFO -
James T. Gunton,
Director -
Efthymios Deliargyris,
Chief Medical Officer -
Jiny Kim,
Director